SUMMARY
Cognitive impairment is a dramatically increasing problem affecting many individuals as well as the health system.
As we have no causal treatment for the loss of memory, symptomatic treatment is needed. Influencing the ACh system
is a generally accepted approach, although other therapeutic treatments are in various stages of development.
The multiple target drug approach using hybrid compounds may be another optimized move forward for the treatment
of cognitive disorders. Since the complex neuronal regulation is slowly being decoded, there is hope that ways
will be found to stop neuronal loss and to generate new synapses.
KEY WORDS
cholin esterase inhibitors; NMDA; receptor antagonist; histaminergic neurotransmission; beta-amyloid peptide; tau-protein; therapy; animal models;
H3 receptor; histamine H3
REFERENCES
Apelt J, Grassmann S, Ligneau X, Pertz HH,
Ganellin CR, Arrang JM, Schwartz JC,
Schunack W, Stark H: Search for histamine H3
receptor antagonists with combined inhibitory
potency at N-methyltransferase: Ether
derivatives. Pharmazie 60:79-106, 2005.
Arrang J, Garbarg M, Lancelot J, Lecomte JM,
Pollard H, Robba M, Schunack W, Schwartz
JC: Highly potent and selective ligands for
histamine H3-receptors. Nature 327:117-123, 1987.
Bacciottini L, Mannaioni PF, Chiappetta M,
Giovannini MG, Blandina P: Acetylcholine
release from hippocampus of freely moving
rats is modulated by thioperamide and
cimetidine. Inflamm Res 48:63-64, 1999.
Bacciottini L, Giovannelli L, Passani MB,
Schunack W, Mannaioni PF, Blandina P:
Endogenous histamine in the medial septumdiagonal
band complex increases the release of
acetylcholine from the hippocampus: A dualprobe
microdialysis study in the freely moving
rat. Eur J Neurosci 15:1669-1680, 2002.
Bamford MJ, Dean DK, Sehmi SS, Wilson DM,
Witherington J: Benzodiazepine derivatives for
the treatment of neurological disorders. WO
2004/056369, 2004.
Barbier AJ, Berridge C, Dugovic C, Laposky AD,
Wilson SJ, Boggs J, Aluisio L, Lord B, Mazur
C, Pudiak CM, Langlois X, Xiao W: Acute
wake-promoting actions of JNJ-5207852, a
novel, diamine-based H3 antagonist. Br J
Pharmacol 143:649-661, 2004.
Bekkers JM: Enhancement by histamine of NMDAmediated
synaptic transmission in the
hippocampus. Science 261:104-106, 1993.
Blandina P, Giorgetti M, Bartolini L, Cecchi M,
Timmerman H, Leurs R, Pepeu G, Giovannini
MG: Inhibition of cortical acetylcholine release
and cognitive performance by histamine H3
receptor activation in rats. Br J Pharmacol
119:1656-1564, 1996.
Block W: Galantamine: Revives memory and helps
fight Alzheimer's. www.galantamine.cc/articles/galantaminearticles-
5.htm (accessed on April 19, 2007).
Bonaventure P, Letavic M, Dugovic C, Wilson S,
Aluisio L, Pudiak C, Lord B, Mazur C, Kamme
F, Nishino S, Carruthers N, Lovenberg T:
Histamine H3 receptor antagonists: From target
indentification to drug leads. Biochem
Pharmacol 73:1084-1096, 2007.
Brown RE, Stevens DR, Haas HL: The physiology
of brain histamine. Prog Neurobiol 63:637-672, 2001.
Bullock R: Future directions in the treatment of
Alzheimer's disease. Expert Opin Investig
Drugs 13:303-314, 2004.
Burns A, O’Brien J: Clinical practice with antidementia
drugs: a consensus statement from
British Association for Psychopharmacology. J
Psychopharmacol 20:732-755, 2006.
Cecchi M, Giorgetti M, Bacciottini L, Giovannini
MG, Blandina P: Increase of acetylcholine
release from cortex of freely moving rats by
administration of histamine into the nucleus
basalis magnocellularis. Inflamm Res 47:32-33, 1998.
Chotard C, Ouimet T, Morisset S, Sahm U,
Schwartz JC, Trottier S: Effects of histamine
H3 receptor agonist and antagonist on
histamine co-transmitter expression in rat
brain. J Neural Transm 109:293-306, 2002.
Coge F, Guenin SP, Rique H, Boutin JA, Galizzi
JP: Structure and expression of the human
histamine H4 receptor gene. Biochem Biophys
Res Commun 284:301-309, 2001.
Cowart M, Faghih R, Gfesser G, Curtis M, Pratt JK,
Bennani Y, Fox GB, Esbenshade TA, Hancock
AA: The medicinal chemistry of novel H3
antagonists. Inflamm Res 53:69-70, 2004a.
Cowart M, Pratt JK, Stewart AO, Bennani YL,
Esbenshade TA, Hancock AA: A new class of
potent non-imidazole H3 antagonists: 2-
aminoethylbenzofurans. Bioorg Med Chem
Lett 14:689-693, 2004b.
Cumming P, Vincent SR: Inhibition of histamine-
N-methyltransferase (HNMT) by fragments of
9-amino-1,2,3,4-tetrahydroacridine (Tacrine)
and by beta-carbolines. Biochem Pharmacol 44:989-992, 1992.
Cummings JL: Cholinesterase inhibitors; a new
class of psychotropic compounds. Am J
Psychiatry 157:4-15, 2000.
Decker JLM, McGaugh JL: The role of interactions
between the cholinergic system and other
neuromodulatory systems in learing and
memory. Synapse 7:151-168, 1991.
Delagarza VW: Pharmacologic treatment of
Alzheimer’s disease: An update. Am Fam
Physician 68:1365-1372, 2003.
Esbenshade TA, Krueger KM, Miller TR, Kang
CH, Denny LI, Witte DG, Yao BB, Fox GB,
Faghih R, Bennani YL, Williams M, Hancock AA: Two novel and selective nonimidazole
histamine H3 receptor antagonists A-304121
and A-317920: I. In vitro pharmacological
effects. J Pharmacol Exp Ther 305:887-896,
2003.
Esbenshade TA, Fox GB, Krueger KM,
Baranowski JL, Miller TR, Kang CH, Denny
LI, Witte DG, Yao BB, Pan JB, Faghih R,
Bennani Y et al.: Pharmacological and
behavioral properties of A-349821, a selective
and potent human histamine H3 receptor
antagonist. Biochem Pharmacol 68:933-945, 2004.
Everitt BJ, Robbins TW: Central cholinergic
systems and cognition. Annu Rev Psychol
48:649-684, 1997.
Everitt BJ, Robbins TW, Muir JL: Reversal of
visual attentional dysfunction following lesions
of the cholinergic basal forebrain by
physostigmine and nicotine but not by the 5-
HT3 receptor antagonist, ondansetron.
Psychopharmacology (Berl.) 118:82-92, 1995.
Fox GB, Pan JB, Esbenshade TA, Bennani YL,
Black LA, Faghih R, Hancock AA, Decker
MW: Effects of histamine H3 receptor ligands
GT-2331 and ciproxifan in a repeated
acquisition avoidance response in the
spontaneously hypertensive rat pup. Behav
Brain Res 131:151-161, 2002.
Fox GB, Pan JB, Radek RJ, Lewis AM, Bitner RS,
Esbenshade TA, Faghih R, Bennani YL,
Williams M, Yao BB, Decker MW, Hancock
AA: Two novel and selective nonimidazole H3
receptor antagonists A-304121 and A-317920:
II. In vivo behavioral and neurophysiological
characterization. J Pharmacol Exp Ther
305:897-908, 2003.
Fox GB, Esbenshade TA, Pan JB, Radek RJ,
Krueger KM, Yao BB, Browman KE, Buckley
MJ, Ballard ME, Komater VA, Miner H,
Zhang M, Faghih R et al.: Pharmacological
properties of ABT-239 [4-(2-{2-[(2R)-2-
methylpyrrolidinyl]ethyl}-benzofuran-5-
yl)benzonitrile]: II. Neurophysiological
characterization and broad preclinical efficacy
in cogntion and schizophrenia of a potent and
selective histamine H3 receptor antagonist. J
Pharmacol Exp Ther 313:176-190, 2005.
Ganellin CR, Leurquin F, Piripitsi A, Arrang JM,
Garbarg M, Ligneau X, Schunack W, Schwartz
JC: Synthesis of potent non-imidazole
histamine H3-receptor antagonists. Arch
Pharm 331:395-404: 1998.
Giorgetti M, Bacciottini L, Bianchi L, Giovannini
MG, Cecchi M, Blandina P: GABAergic
mechanism in histamine H3 receptor inhibition
of K+-evoked release of acetylcholine from rat
cortex in vivo. Inflamm Res 46:33-34, 1997.
Giorgetti M, Bacciottini L, Giovannini MG,
Colivicchi MA, Goldfarb J, Blandina P.: Local
GABAergic modulation of acetylcholine
release from the cortex of freely moving rats.
Eur J Neurosci 12:1941-1948; 2000.
Giovannini MG, Bartolini L, Bacciottini L, Greco
L, Blandina P.: Effects of histamine H3
receptor agonists and antagonists on cognitive
performance and scopolamine-induced
amnesia. Behav Brain Res 104:147-155, 1999.
Givens B, Sarter M: Modulation of cognitive
processes by transsynaptic activation of the
basal forebrain. Behav Brain Res 84:1-22,
1997.
Grassmann S, Apelt J, Sippl W, Ligneau X, Pertz
HH, Zhao YH, Arrang JM, Ganellin CR,
Schwartz JC, Schunack W, Stark H: Imidazole
derivates as a novel class of hybrid compounds
with inhibitory histamine N-methyltransferase
potencies and histamine hH3 receptor affinities.
Bioorg Med Chem 11:2163-2174, 2003.
Green VJ, Pirmohamed M, Kitteringham NR,
Knapp MJ, Park BK: Glutathione S-transferase
mu genotype (GSTM1*0) in Alzheimer's
patients with Tacrine transaminitis. Br J Clin
Pharmacol 39:411-415, 1995.
Hahn B, Shoaib M, Stolerman IP: Nicotine-induced
enhancement of attention in the five-choice
serial reaction time task: The influence of task
demands. Psychopharmacology (Berl.)
162:129-137, 2002.
Hancock AA, Fox GB: Perspectives on cognitive
domains, H3 receptor ligands and neurological
disease. Expert Opin Investig Drugs 13:1237-1248, 2004.
Hancock AA: The challenge of drug discovery of a
GPCR target: Analysis of preclinical
pharmacology of histamine H3
antagonists/inverse agonists. Biochem
Pharmacol 71:1103-1113, 2006.
Holmstedt B: Structure-activity relationship of the
organophosphorus anticholinesterase agents. In
Koelle GB (ed): Cholinesterases and
Anticholinesterase Agents, Berlin, 1963, pp. 429-485.
Hough LB: Genomics meets histamine receptors:
New subtypes, new receptors. Mol Pharmacol
59:415-419, 2001.
Ireland-Denny L, Parihar AS, Miller TR, Kang CH,
Krueger KM, Esbenshade TA, Hancock AA:
Species-related pharmacological heterogeneity
of histamine H3 receptors. Eur J Pharmacol
433:141-150, 2001.
Jann MW: Rivastigmine, a new-generation
cholinesterase inhibitor for the treatment of
Alzheimer's disease. Pharmacotherapy 20:1-12, 2000.
Jia JP, Jia JM, Zhou WD, Xu M, Chu CB, Yan X,
Sun YX: Differential acetylcholine and choline
concentrations in the cerebrospinal fluid of patients with Alzheimer's disease and vascular
dementia. Chin Med J 117:1161-1164, 2004.
Julian PL, Pikl J: The complete synthesis of
Physostigmine (Eserine). J Am Chem Soc
57:755-757, 1935.
Krall WJ, Sramek JJ, Cutler NR: Cholinesterase
inhibitors: A therapeutic strategy for
Alzheimer's disease. Ann Pharmacother 33:441-450, 1999.
LaBella FS, Queen G, Glavin G, Durant G, Stein D,
Brandes LJ: H3 receptor antagonist,
thioperamide, inhibits adrenal steroidogenesis
and histamine binding to adrenocortical
microsomes and binds to cytochrome P450. Br.
J Pharmacol 107:161-164, 1992.
Lane RM, Potkin SG, Enz A: Targeting
acetylcholinesterase and butyrylcholinesterase
in dementia. Int J Neuropsychopharmacol 9:101-124, 2006.
Leurs R, Bakker RA, Timmerman H, de Esch IJ:
The histamine H3 receptor: From gene cloning
to H3 receptor drugs. Nat Rev Drug Discov 4:107-120, 2005.
Ligneau X, Lin J, Vanni-Mercier G, Jouvet M,
Muir JL, Ganellin CR, Stark H, Elz S,
Schunack W, Schwartz J: Neurochemical and
behavioral effects of Ciproxifan, a potent
histamine H3-receptor antagonist. J Pharmacol
Exp Ther 287:658-666: 1998.
Ligneau X, Morisset S, Tardivel-Lacombe J,
Gbahou F, Ganellin CR, Stark H, Schunack W,
Schwartz JC, Arrang JM: Distinct
pharmacology of rat and human histamine H3
receptors: Role of two amino acids in the third
transmembrane domain. Br J Pharmacol
131:1247-1250, 2000.
Ligneau X, Perrin D, Landais L, Camelin JC,
Calmels TP, Berrebi-Bertrand I, Lecomte JM,
Parmentier R, Anaclet C, Lin JS, Bertaina-
Anglade V, la Rochelle CD: BF2.649 [1-{3-[3-
(4-Chlorophenyl)propoxy]propyl}piperidine,
hydrochloride], a nonimidazole inverse
agonist/antagonist at the human histamine H3
receptor: Preclinical pharmacology. J
Pharmacol Exp Ther 320:365-375, 2007.
Lipton SA: Failures and successes of NMDA
receptor antagonists: molecular basis for the
use of open-channel blockers like memantine
in the treatment of acute and chronic
neurologic insults. NeuroRx 1:101-110, 2004.
Liu C, Ma X, Jiang X, Wilson SJ, Hofstra CL,
Blevitt J, Pyati J, Li X, Chai W, Carruthers N,
Lovenberg TW: Cloning and pharmacological
characterization of a fourth histamine receptor
(H4) expressed in bone marrow. Mol
Pharmacol 59:420-426, 2001.
Lleo A, Greenberg SM, Growdon JH: Current
pharmacotherapy for Alzheimer disease. Annu
Rev Med 57:513-533, 2006.
Lovenberg TW, Pyati J, Chang H, Wilson SJ,
Erlander MG.: Cloning of rat histamine H3
receptor reveals distinct species
pharmacological profiles. J Pharmacol Exp
Ther 293:771-778, 2000.
Medhurst AD, Atkins AR, Beresford IJ,
Brackenborough K, Briggs MA, Calver AR,
Cilia J, Cluderay JE, Crook B, Davis JB, Davis
RK, Davis RP et al.: GSK189254 - a novel H3
receptor antagonist that binds to histamine H3
receptors in Alzheimer's Disease brain and
improves cognitive performance in preclinical
models. J Pharmacol Exp Ther 321:1032-1045, 2007.
Meguro KI, Yanai K, Sakai N, Sakurai E, Maeyama
K, Sasaki H, Watanabe T: Effects of
thioperamide, a histamine H3 antagonist, on the
step-through passive avoidance response and
histidine decarboxylase activity in senescenceaccelerated
mice. Pharmacol Biochem Behav
50:321-325, 1995.
Meier G, Apelt J, Reichert U, Grassmann S,
Ligneau X, Elz S, Leurquin F, Ganellin CR,
Schwartz JC, Schunack W, Stark H: Influence
of imidazole replacement in different structural
classes of histamine H3-receptor antagonists.
Eur J Pharm Sci 13:249-259, 2001.
Melnikova I: Therapies for Alzheimer’s disease.
Nat Rev Drug Discov 6:341-342, 2007.
Mochizuki T, Okakura-Mochizuki K, Horii A,
Yamamoto Y, Yamatodani A: Histaminergic
modulation of hippocampal acetylcholine
release in vivo. J Neurochem 62:2275-2282,
1994.
Monti JM: Involvement of histamine in the control
of the waking state. Life Sci 53:1331-1338,
1993.
Morisset S, Traiffort E, Schwartz JC: Inhibition of
histamine versus acetylcholine metabolism as a
mechanism of Tacrine activity. Eur J
Pharmacol 315:R1-R2, 1996.
Morphy R, Kay C, Rankovic Z: From magic bullets
to designed multiple ligands. Drug Discov
Today 9:641-651, 2004.
Muir JL, Everitt BJ, Robbins TW: AMPA-induced
excitotoxic lesions of the basal forebrain: a
significant role for the cortical cholinergic
system in attentional function. J Neurosci 14:2313-2326, 1994.
Munoz-Torrero D, Camps P: Dimeric and hybrid
anti-Alzheimer drug candidates: Curr Med
Chem 13:399-422, 2006.
Neumann R, Peter HH: Insecticidal
organophosphates: Nature made them first.
Experientia 43:1235-1237, 1987.
Orr EL, Quay WB: The effects of castration on
histamine levels and 24-hour rhythm in the
male rat hypothalamus. Endocrinology 96:941-945, 1984.
Ortho-Mcneil neurologics: http://www.rxforsafety.com/news/index.htm
(accessed on April 19, 2007).
Panula P, Rinne J, Kuokkanen K, Eriksson KS,
Sallmen T, Kalimo H, Relja M: Neuronal
histamine deficit in Alzheimer's disease.
Neuroscience 82:993-997, 1997.
Passani MB, Blandina P: Cognitive implications for
H3 and 5-HT3 receptor modulation of cortical
cholinergic function: A parallel story. Methods
Find Exp Clin Pharmacol 20:725-733, 1998.
Passani MB, Blandina P: The neuronal
histaminergic system in cognition. Curr Med
Chem CNS Agents 4:17-26, 2004.
Passani MB, Cangioli I, Baldi , Bucherelli C,
Mannaioni PF, Blandina P: Histamine H3
receptor-mediated impairment of contextual
fear conditioning and in-vivo inhibition of
cholinergic transmission in the rat basolateral
amygdala. Eur J Neurosci 14:1522-1532,
2001.
Passani MB, Lin JS, Hancock A, Crochet S,
Blandina P: The histamine H3 receptor as a
novel therapeutic target for cognitive and sleep
disorders. Trends Pharmacol Sci 25:618-625,
2004.
Petroianu G, Arafat K, Sasse BC, Stark H: Multiple
enzyme inhibitions by histamine H3 receptor
antagonists as potential procognitive agents.
Pharmazie 61:179-182, 2005.
Plaitakis A, Duvoisin RC: Homer's moly identified
as Galanthus nivalis L.: Physiologic antidote to
Stramonium poisoning. Clin Neuropharmacol
6:1-5, 1983.
Prast H, Fischer H, Prast M, Philippu A: In vivo
modulation of histamine release by
autoreceptors and muscarinic acetylcholine
receptors in the rat anterior hypothalamus.
Naunyn Schmiedebergs Arch Pharmacol 350:599-604, 1994.
Prast H, Fischer H, Tran MH, Grass K, Lamberti C,
Philippu A: Modulation of acetylcholine
release in the ventral striatum by histamine
receptors. Inflamm Res 46:37-38, 1997.
Proudfoot A: The early toxicology of
Physiostigmine: A tale of beans, great men and
egos. Toxicol Rev 25:99-138, 2006.
Rogawski MA, Wenk GL: The
neuropharmacological basis for the use of
memantine in the treatment of Alzheimer's
disease. CNS Drug Rev 9:275-308, 2003.
Roth BL, Sheffler DJ, Kroeze WK: Magic shotguns
versus magic bullets: Selectively non-selective
drugs for mood disorders and schizophrenia.
Drug Discov Today 3:353-359, 2004.
Selbach O, Brown RE, Haas HL: Long-term
increase of hippocampal excitability by
histamine and cyclic AMP.
Neuropharmacology 36:1539-1548, 1997.
Schlicker E, Betz R, Gothert M: Histamine H3
receptor-mediated inhibition of serotonin
release in the rat brain cortex. Naunyn
Schmiedebergs Arch Pharmacol 337:588-590, 1988.
Schlicker E, Fink K, Detzner M, Gothert M:
Histamine inhibits dopamine release in the
mouse striatum via presynaptic H3 receptors. J
Neural Transm 93:1-10, 1993.
Schlicker E, Fink K, Hinterhaner M, Gothert M:
Inhibition of noradrenaline release in the rat
brain cortex via presynaptic H3 receptors.
Naunyn Schmiedebergs Arch Pharmacol 340:633-638, 1989.
Schlicker E, Werthwein S, Zentner J: Histamine H3
receptor-mediated inhibition of noradrenaline
release in the human brain. Fundam Clin
Pharmacol 13:120-122, 1999.
Stark H: Recent advances in histamine H3/H4
receptor ligands. Expert Opin Ther Pat 13:851-865, 2004a.
Stark H: Turning from monogamy to strategic
promiscuity. Drug Discov Today 9:736-737, 2004b.
Sugimoto H, Ogura H, Arai Y, Iimura Y,
Yamanishi: Research and development of
Donepezil hydrochloride, a new type of
acetylcholinesterase inhibitor. Jpn J
Pharmacol 89:7-20, 2002.
Summers WK: Tacrine, and Alzheimer's
treatments. J Alzheimers Dis 9:439-445, 2006.
Tedford CE, Hoffmann M, Seyedi N, Maruyama R,
Levi R, Yates SL, Ali SM, Phillips JG: High
antagonist potency of GT-2227 and GT-2331,
new histamine H3 receptor antagonists, in two
functional models. Eur J Pharmacol 351:307-311, 1998.
Ting P, Aslanian R, Berlin MY, Boyce CW; Cao J;
Mangiaracina P; Mc Cormick KD; Mutahi
MW; Rosenblum SB; Shih NY; Solomon DM;
Tom WC; Zeng Q: 1-(4-
Piperidinyl)benzimidazolones as histamine H3
antagonists. WO-03103669, 2003.
Tuomisto L, Tuomisto J: Diurnal variations in brain
and pituitary histamine and histamine-Nmethyltransferase
in the rat and guinea pig.
Med Biol 60:204-209, 1982.
Wada H, Inagaki N, Yamatodani A, Watanabe T: Is
the histaminergic neuron system a regulatory
center for whole-brain activity? Trends
Neurosci 14:415-418, 1991.
Wimo A, Winblad B, Aguero-Torres H, von Strauss
E: The magnitude of dementia occurrence in
the world. Alzheimer Dis Assoc Disord
17:63-67, 2003.
Yang R, Hey JA, Aslanian R, Rizzo CA:
Coordination of histamine H3 receptor
antagonists with human adrenal cytochrome P450 enzymes. Pharmacology 66:128-135, 2002.
Yao BB, Hutchins CW, Carr TL, Cassar S, Masters
JN, Bennani YL, Esbenshade TA, Hancock
AA: Molecular modeling and pharmacological
analysis of species-related histamine H3
receptor heterogeneity. Neuropharmacology
44:773-786, 2003.
|
CITED
Sander K, Kottke T, Stark H: Histamine H-3 Receptor Antagonists Go to Clinics. Biol Pharm Bull 31:2163-2181, 2008.
Isensee K, Amon M, Galaparti A, Ligneau X, Camelin J-C, Capet M, Schwartz J-C, Stark H: Fluorinated non-imidazole histamine H-3 receptor antagonists. Bioorg
Med Chem Lett 19:2172-2175, 2009.
Johnson CN, Ahmed M, Miller ND: 5-HT6 receptor antagonists: Prospects for the treatment of cognitive disorders including dementia. Curr Opin Drug Discovery Dev
11:642-654, 2008.
|
